{"database": "lobbying", "table": "lobbying_activities", "rows": [[1911999, "81800efa-03ff-4867-9deb-d20cad0b3ec0", "Q4", "RED+BLUE STRATEGIES", 400693064, "EXPRESS SCRIPTS INC.", 2016, "fourth_quarter", "PHA", "P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.\n\nH.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid funding and other prescription drug related issues. \n\nNational Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. \n\nThe Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.  \n\nThe Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders.  Particular focus on formulary policies. \n\nImplementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.\n\nPolicies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.\n\nIssues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs.\n\nIssues related to the pricing of prescription medications.\n\nRules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. \n\nIssues related to the treatment of pharmacy benefit managers in federal programs. \n\nPolicies related to stopping the diversion of prescription medications in the nation's drug supply chain. \n\nIssues related to access and affordability for prescription medications for both government and private sector benefit programs.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2017-01-12T16:08:09-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1911999"], "units": {}, "query_ms": 33.04337908048183, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}